Skip to content

Axsome Therapeutics AXSM Warrants Issued With Debt Financing

Discontinued — last reported Q4 '23

Warrants Issued With Debt Financing at other companies

Joby Aviation logo
Joby AviationJOBY
$29.46M-51.9%
Rocket Lab USA, Inc. logo
Rocket Lab USA, Inc.RKLB
$0
General Purpose Acquisition Corp.
 logo
General Purpose Acquisition Corp. GPAC
$948.13K+80.6%
Apollo Global Management logo
Apollo Global ManagementAPO
$0-100%
AST SpaceMobile logo
AST SpaceMobileASTS
$8.65M
Jaguar Uranium
 logo
Jaguar Uranium JAGU
70K

Other financials

Income statement

See full
Revenue$191.2M+57.4%
Gross profit$176.5M+58.0%
Operating income-$63.4M-11.2%
Net income-$64.5M-8.6%
EPS (diluted)-$1.26-3.3%

Balance sheet

See full
Cash & equivalents$305.1M+1.4%
Total debt$219.9M+4.1%
Total equity$54.6M+2.6%
Total assets$713.6M+19.6%

Cash flow

See full
Operating cash flow-$20.7M+52.3%
CapEx$121.0K-64.2%
Free cash flow-$20.8M+52.4%

Valuation

See full
Market cap$12.89B+52.0%
Enterprise value$12.81B+52.9%
P/S18.2×-1.4×

Profitability

See full
Gross margin92.6%+1.1pp
Operating margin-24.4%-9.3pp
Net margin-26.6%-9.8pp
FCF margin-10.2%-3.9pp

Returns & leverage

See full
Return on equity-349.4%+109pp
Debt / equity+0.1×
Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept axsm:WarrantsIssuedWithDebtFinancing.

The official record: Axsome Therapeutics’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's warrants issued with debt financing.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axsome Therapeutics's warrants issued with debt financing?
Axsome Therapeutics (AXSM) reported warrants issued with debt financing of $408.75K in Q4 2023.
What does warrants issued with debt financing mean?
Equity warrants granted to lenders as part of a debt financing deal.
How do you interpret warrants issued with debt financing?
Frequent use may indicate a higher cost of traditional debt or a need to incentivize lenders in capital-constrained environments.
How does warrants issued with debt financing compare across companies?
Common in clinical-stage biopharma companies with limited revenue and higher credit risk profiles.